Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Willemijn Maria Gommans is active.

Publication


Featured researches published by Willemijn Maria Gommans.


BioEssays | 2009

RNA editing: a driving force for adaptive evolution?

Willemijn Maria Gommans; Sean P. Mullen; Stefan Maas

Genetic variability is considered a key to the evolvability of species. The conversion of an adenosine (A) to inosine (I) in primary RNA transcripts can result in an amino acid change in the encoded protein, a change in secondary structure of the RNA, creation or destruction of a splice consensus site, or otherwise alter RNA fate. Substantial transcriptome and proteome variability is generated by A‐to‐I RNA editing through site‐selective post‐transcriptional recoding of single nucleotides. We posit that this epigenetic source of phenotypic variation is an unrecognized mechanism of adaptive evolution. The genetic variation introduced through editing occurs at low evolutionary cost since predominant production of the wild‐type protein is retained. This property even allows exploration of sequence space that is inaccessible through mutation, leading to increased phenotypic plasticity and provides an evolutionary advantage for acclimatization as well as long‐term adaptation. Furthermore, continuous probing for novel RNA editing sites throughout the transcriptome is an intrinsic property of the editing machinery and represents the molecular basis for increased adaptability. We propose that higher organisms have therefore evolved to systems with increasing RNA editing activity and, as a result, to more complex systems.


PLOS ONE | 2009

Novel Exon of Mammalian ADAR2 Extends Open Reading Frame

Stefan Maas; Willemijn Maria Gommans

Background The post-transcriptional processing of pre-mRNAs by RNA editing contributes significantly to the complexity of the mammalian transcriptome. RNA editing by site-selective A-to-I modification also regulates protein function through recoding of genomically specified sequences. The adenosine deaminase ADAR2 is the main enzyme responsible for recoding editing and loss of ADAR2 function in mice leads to a phenotype of epilepsy and premature death. Although A-to-I RNA editing is known to be subject to developmental and cell-type specific regulation, there is little knowledge regarding the mechanisms that regulate RNA editing in vivo. Therefore, the characterization of ADAR expression and identification of alternative ADAR variants is an important prerequisite for understanding the mechanisms for regulation of RNA editing and the causes for deregulation in disease. Methodology/Principal Findings Here we present evidence for a new ADAR2 splice variant that extends the open reading frame of ADAR2 by 49 amino acids through the utilization of an exon located 18 kilobases upstream of the previously annotated first coding exon and driven by a candidate alternative promoter. Interestingly, the 49 amino acid extension harbors a sequence motif that is closely related to the R-domain of ADAR3 where it has been shown to function as a basic, single-stranded RNA binding domain. Quantitative expression analysis shows that expression of the novel ADAR2 splice variant is tissue specific being highest in the cerebellum. Conclusions/Significance The strong sequence conservation of the ADAR2 R-domain between human, mouse and rat ADAR2 genes suggests a conserved function for this isoform of the RNA editing enzyme.


RNA | 2008

Screening of human SNP database identifies recoding sites of A-to-I RNA editing

Willemijn Maria Gommans; Nicholas E. Tatalias; Christina P. Sie; Dylan E. Dupuis; Nicholas Vendetti; Lauren Smith; Rikhi Kaushal; Stefan Maas

Single nucleotide polymorphisms (SNPs) are DNA sequence variations that can affect the expression or function of genes. As a result, they may lead to phenotypic differences between individuals, such as susceptibility to disease, response to medications, and disease progression. Millions of SNPs have been mapped within the human genome providing a rich resource for genetic variation studies. Adenosine-to-inosine RNA editing also leads to the production of RNA and protein sequence variants, but it acts on the level of primary gene transcripts. Sequence variations due to RNA editing may be misannotated as SNPs when relying solely on expressed sequence data instead of genomic material. In this study, we screened the human SNP database for potential cases of A-to-I RNA editing that cause amino acid changes in the encoded protein. Our search strategy applies five molecular features to score candidate sites. It identifies all previously known cases of editing present in the SNP database and successfully uncovers novel, bona fide targets of adenosine deamination editing. Our approach sets the stage for effective and comprehensive genome-wide screens for A-to-I editing targets.


PLOS ONE | 2012

A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability

Jos Bernard Poell; Rick J. van Haastert; Thijs de Gunst; Iman Johannes Schultz; Willemijn Maria Gommans; Mark Verheul; Francesco Cerisoli; Paula I. van Noort; Grégoire Pierre André Prevost; Roel Q. J. Schaapveld; Edwin Cuppen

Malignant melanoma is an aggressive form of skin cancer with poor prognosis. Despite improvements in awareness and prevention of this disease, its incidence is rapidly increasing. MicroRNAs (miRNAs) are a class of small RNA molecules that regulate cellular processes by repressing messenger RNAs (mRNAs) with partially complementary target sites. Several miRNAs have already been shown to attenuate cancer phenotypes, by limiting proliferation, invasiveness, tumor angiogenesis, and stemness. Here, we employed a genome-scale lentiviral human miRNA expression library to systematically survey which miRNAs are able to decrease A375 melanoma cell viability. We highlight the strongest inhibitors of melanoma cell proliferation, including the miR-15/16, miR-141/200a and miR-96/182 families of miRNAs and miR-203. Ectopic expression of these miRNAs resulted in long-term inhibition of melanoma cell expansion, both in vitro and in vivo. We show specifically miR-16, miR-497, miR-96 and miR-182 are efficient effectors when introduced as synthetic miRNAs in several melanoma cell lines. Our study provides a comprehensive interrogation of miRNAs that interfere with melanoma cell proliferation and viability, and offers a selection of miRNAs that are especially promising candidates for application in melanoma therapy.


Nucleic Acids Research | 2009

Identification of a selective nuclear import signal in adenosine deaminases acting on RNA

Stefan Maas; Willemijn Maria Gommans

The adenosine deaminases acting on RNA (ADARs) comprise a family of RNA editing enzymes that selectively modify single codons within RNA primary transcripts with often profound impact on protein function. Little is known about the mechanisms that regulate nuclear RNA editing activity. Editing levels show cell-type specific and developmental modulation that does not strictly coincide with observed expression levels of ADARs. Here, we provide evidence for a molecular mechanism that might control nuclear import of specific ADARs and, in turn, nuclear RNA editing. We identify an in vivo ADAR3 interaction partner, importin alpha 1 (KPNA2) that specifically recognizes an arginine-rich ADAR3 sequence motif and show that it acts as a functional nuclear localization sequence. Furthermore, whereas KPNA2, but not KPNA1 or KNPA3, recognizes the ADAR3 NLS, we observe the converse binding specificity with ADAR2. Interestingly, alternative splicing of ADAR2 pre-mRNA introduces an ADAR3-like NLS that alters the interaction profile with the importins. Thus, in vivo RNA editing might be regulated, in part, through controlled subcellular localization of ADARs, which in turn is governed by the coordinated local expression of importin α proteins and ADAR protein variants.


Biochemical and Biophysical Research Communications | 2011

Genome-wide evaluation and discovery of vertebrate A-to-I RNA editing sites.

Stefan Maas; C.P. Godfried Sie; I. Stoev; D.E. Dupuis; J. Latona; A.M. Porman; B. Evans; P. Rekawek; V. Kluempers; M. Mutter; Willemijn Maria Gommans; Daniel P. Lopresti

RNA editing by adenosine deamination, catalyzed by adenosine deaminases acting on RNA (ADAR), is a post-transcriptional modification that contributes to transcriptome and proteome diversity and is widespread in mammals. Here we administer a bioinformatics search strategy to the human and mouse genomes to explore the landscape of A-to-I RNA editing. In both organisms we find evidence for high excess of A/G-type discrepancies (inosine appears as a guanosine in cloned cDNA) at non-polymorphic, non-synonymous codon sites over other types of discrepancies, suggesting the existence of several thousand recoding editing sites in the human and mouse genomes. We experimentally validate recoding-type A-to-I RNA editing in a number of human genes with high scoring positions including the coatomer protein complex subunit alpha (COPA) as well as cyclin dependent kinase CDK13.


Analytical Biochemistry | 2010

A mammalian reporter system for fast and quantitative detection of intracellular A-to-I RNA editing levels

Willemijn Maria Gommans; Jill McCane; Gregory S. Nacarelli; Stefan Maas

An important molecular mechanism to create protein diversity from a limited set of genes is A-to-I RNA editing. RNA editing converts single adenosines into inosines in pre-mRNA. These single base conversions can have a wide variety of consequences. Editing can lead to codon changes and, consequently, altered protein function. Moreover, editing can alter splice sites and influences miRNA biogenesis and target recognition. The two enzymes responsible for editing in mammals are adenosine deaminase acting on RNA (ADAR) 1 and 2. However, it is currently largely unknown how the activity of these enzymes is regulated in vivo. Editing activity does not always correlate with ADAR expression levels, suggesting posttranscriptional or posttranslational mechanisms for controlling activity. To investigate how editing is regulated in mammalian cells, we have developed a straightforward quantitative reporter system to detect editing levels. By employing luciferase activity as a readout, we could easily detect different levels of editing in a cellular context. In addition, increased levels of ADAR2 correlated with increased levels of luciferase activity. This reporter system therefore sets the stage for the effective screening of cDNA libraries or small molecules for strong modulators of intracellular editing to ultimately elucidate how A-to-I editing is regulated in vivo.


Biochemical and Biophysical Research Communications | 2008

Characterization of ADAR1-mediated modulation of gene expression.

Willemijn Maria Gommans; Stefan Maas

Conversion of adenosine into inosine in RNA molecules constitutes an important post-transcriptional mechanism for generating transcript diversity and is catalyzed by adenosine deaminases acting on RNA (ADARs). Intriguingly, we observed that the editing enzyme ADAR1 enhances reporter gene expression in a cellular, plasmid-based system. The induction of gene expression is independent of the used reporter transgene or the promoter type, but relies on the RNA editing activity and specificity of ADAR1. More detailed analysis indicates that the effect is due to enhanced reporter gene transcription. Induction of gene expression by ADAR1 is lost when the reporter expression cassette is placed in a chromosomal environment. Our results suggest that a cellular, ADAR1-specific RNA editing substrate causes upregulation of plasmid-based gene expression.


Archive | 2007

Diversifying Exon Code through A‐to‐I RNA Editing

Willemijn Maria Gommans; Dylan E. Dupuis; Jill McCane; Nicholas E. Tatalias; Stefan Maas


Archive | 2012

Mirna for treating diseases and conditions associated with neo-angiogenesis

Sanne Weijzen; Roeland Quirinus Jozef Schaapveld; Meriem Bourajjaj; Haastert Rick Jan van; Arjan Willem Griffioen; Beijnum Judith Rosina Van; Edwin Cuppen; Eugene Berezikov; Puijenbroek Andreas Alphons Franciscus Ludovicus Van; Willemijn Maria Gommans

Collaboration


Dive into the Willemijn Maria Gommans's collaboration.

Top Co-Authors

Avatar

Eugene Berezikov

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge